We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.3B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 151 increasing their positions, 197 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

38% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 47

23% more capital invested

Capital invested by funds: $14B → $17.3B (+$3.3B)

3% more funds holding

Funds holding: 530544 (+14)

1.19% more ownership

Funds ownership: 16.09%17.28% (+1.2%)

23% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 197

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
544
Holders Change
+14
Holders Change %
+2.64%
% of All Funds
12.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
65
Increased
151
Reduced
197
Closed
47
Calls
$225M
Puts
$73.5M
Net Calls
+$152M
Net Calls Change
+$45M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$2.54B +$87.5M +1,156,707 +4%
Primecap Management
2
Primecap Management
California
$2.19B +$89.4M +1,182,006 +4%
Dodge & Cox
3
Dodge & Cox
California
$2.02B -$61.8M -817,250 -3%
Jennison Associates
4
Jennison Associates
New York
$1.57B +$774M +10,235,068 +106%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$1.4B +$570M +7,541,304 +75%
Bank of America
6
Bank of America
North Carolina
$1.08B -$123M -1,629,887 -11%
Fisher Asset Management
7
Fisher Asset Management
Washington
$535M +$16.5M +218,391 +3%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$522M -$14.2M -188,050 -3%
Capital International Investors
9
Capital International Investors
California
$386M +$12.1M +159,708 +3%
EIP
10
Epoch Investment Partners
New York
$298M -$19.7M -260,956 -6%
Capital World Investors
11
Capital World Investors
California
$277M +$303 +4 +0%
BlackRock
12
BlackRock
New York
$256M -$5.91M -78,076 -2%
Arrowstreet Capital
13
Arrowstreet Capital
Massachusetts
$224M +$157M +2,072,073 +273%
PI
14
Putnam Investments
Massachusetts
$175M +$1.02M +13,442 +0.6%
Franklin Resources
15
Franklin Resources
California
$141M +$76.2M +1,007,608 +131%
Northern Trust
16
Northern Trust
Illinois
$140M +$2.65M +35,080 +2%
FCM
17
Farallon Capital Management
California
$135M -$16.3M -215,000 -11%
Wells Fargo
18
Wells Fargo
California
$131M -$17.4M -230,138 -12%
Goldman Sachs
19
Goldman Sachs
New York
$118M +$25.9M +342,045 +30%
RJA
20
Raymond James & Associates
Florida
$117M -$22.3M -295,323 -17%
GQG Partners
21
GQG Partners
Florida
$106M +$102M +1,344,394 New
PPA
22
Parametric Portfolio Associates
Washington
$104M -$4.06M -53,614 -4%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$103M -$525K -6,942 -0.5%
Morgan Stanley
24
Morgan Stanley
New York
$97.3M +$4.81M +63,608 +5%
Federated Hermes
25
Federated Hermes
Pennsylvania
$96.7M -$49.8M -658,260 -35%

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.3B — up 23% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new AZN positions and 47 closed out — a net gain of 18 holders — while 151 added to existing stakes and 197 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 530 in Q2 2018.
  • Funds reported $17.3B of AstraZeneca stock for Q3 2018, up 23% quarter-over-quarter.
  • 65 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +18 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.